Selected article for: "protective immunity and vaccine candidate"
Author: Chiuppesi, Flavia; Salazar, Marcela d’Alincourt; Contreras, Heidi; Nguyen, Vu H.; Martinez, Joy; Park, Yoonsuh; Nguyen, Jenny; Kha, Mindy; Iniguez, Angelina; Zhou, Qiao; Kaltcheva, Teodora; Levytskyy, Roman; Ebelt, Nancy D.; Kang, Tae Hyuk; Wu, Xiwei; Rogers, Thomas F.; Manuel, Edwin R.; Shostak, Yuriy; Diamond, Don J.; Wussow, Felix
Title: Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform
  • Cord-id: laahc5zz
  • Document date: 2020_11_30
    • ID: laahc5zz
    Snippet: Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We demonstrate the construction of a vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we use this vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressi
    Document: Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We demonstrate the construction of a vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we use this vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. We show that mice immunized with these sMVA vectors develop robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and additional hour: 1, 2
    • acute respiratory syndrome and ade infection antibody dependent enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and ade mediate: 1, 2
    • acute respiratory syndrome and local site: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and low coverage: 1, 2, 3, 4, 5
    • acute respiratory syndrome and low dose vaccine: 1, 2, 3, 4
    • acute respiratory syndrome and low frequency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute respiratory syndrome and low high dose immunization: 1
    • acute respiratory syndrome and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute respiratory syndrome and luciferase assay system: 1
    • acute respiratory syndrome and luciferase lentiviral vector: 1
    • acute respiratory syndrome and luria bertani: 1
    • acute respiratory syndrome and luria bertani lb medium: 1
    • acute respiratory syndrome and lymphopenia correlation: 1, 2
    • acute respiratory syndrome and lysis buffer: 1, 2, 3
    • adaptive immune response and ade mediate: 1
    • adaptive immune response and local site: 1
    • adaptive immune response and luciferase activity: 1